189 results
8-K
EX-4.1
APVO
Aptevo Therapeutics Inc
15 Apr 24
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
4:17pm
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required
8-K
EX-10.1
APVO
Aptevo Therapeutics Inc
15 Apr 24
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
4:17pm
) only, the Company shall not be responsible for any Liabilities or Expenses of any Indemnified Person that are finally judicially determined to have … Person; provided that the Company shall not in such event be responsible hereunder for the fees and expenses of more than one firm of separate counsel
8-K
EX-10.2
APVO
Aptevo Therapeutics Inc
15 Apr 24
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
4:17pm
and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one … be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained
8-K
EX-4.2
APVO
Aptevo Therapeutics Inc
15 Apr 24
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
4:17pm
is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
UPLOAD
cf4dkbpo 66yrvk38
29 Nov 23
Letter from SEC
12:00am
8-K
EX-4.4
jgg72a4jqp7win
9 Nov 23
Entry into a Material Definitive Agreement
5:17pm
8-K
EX-4.3
oq5i9 xx6
9 Nov 23
Entry into a Material Definitive Agreement
5:17pm